Shares of Endo International (NASDAQ: ENDP) came in crashing after The Wall Street Journal reported that the drugmaker had engaged Alvarez & Marsal to look into a potential financial restructuring. The report of a potential restructuring is only the latest of woes Endo has faced related to a flood of opioid-related lawsuits.
Why is Endo’s share price dropping?
Aug 20, 2021 · The drugmaker could be evaluating financial restructuring options. What happened Shares of Endo International ( ENDP -5.63% ) were crashing 28.6% lower as of 11:07 a.m. EDT on Friday. The big...
Why are Endo International shares crashing?
Mar 02, 2022 · Endo International has a 52-week high of $8.74 and a 52-week low of $1.94. At the time of publication, shares were trading 19.03% lower at …
What happened to Endo International plc (ENDP)?
Mar 02, 2022 · Endo International also says fourth-quarter 2021 sterile injectables segment revenues were $319 million, a decrease of 4% compared to $332 million during fourth-quarter 2020. The company says this...
Why is Endo stock dropping?
Teva and Endo Stock Are Falling Because Opioid Suits Aren't Going Away. Teva Pharmaceutical Industries and Endo International stock were down Monday morning after a Morgan Stanley analyst downgraded them both, citing the ongoing litigation over prescription opioid sales.Jul 15, 2019
Is Endo a good stock to buy?
Endo International plc - Sell Valuation metrics show that Endo International plc may be undervalued. Its Value Score of A indicates it would be a good pick for value investors. The financial health and growth prospects of ENDP, demonstrate its potential to outperform the market. It currently has a Growth Score of C.
Who owns Endo Pharmaceuticals?
In 1969, E.I. du Pont de Nemours and Company (DuPont) acquired Endo.
What is Endo Pharmaceuticals known for?
Endo Pharmaceuticals Inc., headquartered in Malvern, PA, develops and markets high-value, quality branded pharmaceutical products for patients in need. Endo Pharmaceuticals' specialty portfolio includes products for urology, men's health, orthopedics and endocrinology.
Is Endo Pharmaceuticals a buy?
Endo International has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.
Who bought Par Pharmaceuticals?
Endo InternationalIreland-based Endo International has completed the $8.05bn acquisition of US-based Par Pharmaceutical Holdings from private investment firm TPG Capital North America.Sep 28, 2015
Who is the CEO of Endo Pharmaceuticals?
Blaise Coleman (Mar 6, 2020–)Endo International / CEO
When did Endo buy par?
Endo Completes Acquisition of Par Pharmaceutical and Provides Financial Guidance. DUBLIN , Sept. 28, 2015 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced it has completed its previously announced $8.05 billion acquisition of Par Pharmaceutical Holdings, Inc.Sep 28, 2015
What drugs does Endo international make?
AVEED® (testosterone undecanoate) injection CIIIFull Prescribing Information Including Boxed Warning, and Medication Guide AVEEDUSA.com AVEEDREMS.comEDEX® (alprostadil for injection)Full Prescribing InformationFORTESTA® (testosterone) Gel CIIIFull Prescribing Information Including Boxed Warning, and Medication Guide13 more rows
What does prefix Endo mean?
withina combining form meaning “within,” used in the formation of compound words: endocardial.
What is the scientific meaning of endo?
within, inside or internalThe prefix (end- or endo-) means within, inside or internal.May 16, 2019
Endo's Earnings & Revenues Surpass Estimates in Q4
The company’s earnings of 75 cents easily beat the Zacks Consensus Estimate of 50 cents in the reported quarter but decreased from 80 cents in the year-ago quarter.
Quarterly Highlights
Endo has four reportable business segments — Branded Pharmaceuticals, Generic Pharmaceuticals, Sterile Injectables and International Pharmaceuticals.
2020 Results
Revenues in 2020 came in at $2.9 billion, declining slightly from $2.91 billion in 2019 but easily beating the Zacks Consensus Estimate of $2.80 billion.
Signals & Forecast
A buy signal was issued from a pivot bottom point on Wednesday, September 01, 2021, and so far it has risen 3.81%. Further rise is indicated until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal.
Support, Risk & Stop-loss
Endo International plc finds support from accumulated volume at $2.15 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Endo International plc stock A Buy?
Endo International plc holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Strong First Quarter
Endo posted non-GAAP earnings a share of 73 cents despite revenue falling 12.5% Y/Y to $717.9 million. It also issued full-year 2021 revenue guidance of $2.65 billion to $2.79 billion, above consensus estimates. The stock's underperformance running contrary to its strong quarter raised its value and profitability score.
Outlook
Endo raised the bottom range of the adjusted EBITDA and adjusted diluted net income per share forecast:
Risks
The opioid litigation remains a headwind for Endo. President and Chief Executive Officer Coleman said "we strongly disagree with the court's default order on liability. I'd also like to clarify that, despite certain press reports, that there has been no finding to date that Endo's owes any amount as a result of the default order."
Your Takeaway
The Opioid litigation is the biggest headwind to Endo stock between now and late summer. Investors may bet on the court siding with the company. After that, investors may use this five-year discounted cash flow EBITDA Exit model to estimate a fair value.
An FDA approval boosted the pharma stock
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
What happened
Shares of Endo International ( NASDAQ:ENDP) were jumping 5.7% higher as of 11:26 a.m. EDT on Tuesday after rising as much as 15.6% earlier in the day. The gain came following the drugmaker's announcement on Monday evening that the FDA approved Qwo for treating moderate to severe cellulite in the buttocks of adult women.
So what
Investors cheered the FDA approval of Qwo for good reason. The agency's thumbs-up for the cellulite treatment marked Endo's move into medical aesthetics, a potentially lucrative arena for the company.
Now what
Don't expect Qwo to make a financial impact on the pharma stock anytime soon. Endo decided to delay its launch of the product until 2021 due to the COVID-19 pandemic. The company said that Qwo should be available in aesthetic healthcare practitioners' offices beginning next spring.